- Clinical Trials
- April 2025
- 60 Pages
Global
From €1108EUR$1,250USD£954GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1108EUR$1,250USD£954GBP
- Report
- June 2025
- 110 Pages
Global
From €4342EUR$4,900USD£3,739GBP
- Report
- March 2025
- 200 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- April 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- January 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP
- Report
- July 2025
- 182 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- July 2025
- 129 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- June 2025
- 146 Pages
Global
From €2658EUR$2,999USD£2,289GBP
- Report
- January 2025
- 175 Pages
Global
From €3979EUR$4,490USD£3,427GBP

Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery.
Factor IX is a part of the larger hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia.
Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less Read more